Catalyst catapults on FDA 'breakthrough' for rare autoimmune disease drug
This article was originally published in Scrip
Executive Summary
Shares of Catalyst Pharmaceutical Partners catapulted 76% on 27 August on news the FDA granted breakthrough therapy designation to the Florida specialty pharma's experimental drug Firdapse (amifampridine phosphate), which is under investigation to treat symptoms associated with Lambert-Eaton Myasthenic syndrome (LEMS), a rare autoimmune disease, which results in muscle weakness, particularly in the legs and trunk.
You may also be interested in...
Phase III Data Support Catalyst's NDA Resubmission For Firdapse
Catalyst executives note that the company has completed everything the FDA requested to support resubmission of Firdapse for its first two rare disease indications – a second Phase III study in LEMS and abuse liability studies.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.